PostScript

LETTERS TO THE EDITOR

Conventional RIA underestimates cortisol suppression in the presence of prednisolone

Concerns about suppression of the hypothalamic pituitary adrenal (HPA) axis by systemic steroids as well as by inhaled corticosteroids have been widely held since their introduction. Several studies have suggested that inhaled corticosteroids can replace oral corticosteroids during exacerbations of asthma¹ and in severe asthma.² We have recently published a study in which treatment of unstable asthmatic patients for 2 weeks with high doses of inhaled fluticasone resulted in a greater improvement in airway hyperresponsiveness than oral prednisolone.³ Additionally—and to our surprise—we found a comparable decrease in serum cortisol levels with fluticasone 1000 µg twice daily and oral prednisolone 30 mg/day. A radioimmunoassay (RIA) method was used to determine serum cortisol suppression in blood with corticosteroid treatment, as in most studies published to date.^{4,5} However, prednisolone and its metabolites are known to be chemically similar to serum cortisol and might therefore interfere with cortisol measurements by RIA.⁶ Analytical methods involving chromatographic separation of cortisol from prednisolone and its metabolites, such as high performance liquid chromatography (HPLC), circumvent this problem of interference.

We compared serum cortisol measurements by both conventional RIA and by HPLC in the same study,³ which was of a double blind, double dummy, three arm parallel group design. Patients received either oral prednisolone (30 mg/day), fluticasone propionate 1000 µg twice daily (FP2000), or fluticasone propionate 250 µg twice daily (FP500), both via Diskhaler dry powder inhalation. Measurements at the start of the study and after 2 weeks of treatment were performed at the same time in the morning.

The Gilson ASTED (automated sequential trace enrichment of dialysates) system was used followed by separation with HPLC and detection by UV absorbency.⁷ The upper and lower limits of measurement were found to be

Figure 1 Change in mean (SE) serum cortisol level (%) from baseline in the three treatment groups measured by conventional radioimmunoassay (RIA) and high performance liquid chromatography (HPLC).

688 and 6.9 nmol/l, respectively, and the coefficient of variation ranged from 5.6% to 7.0%.

For RIA analysis samples were homogenised and diluted at +60°C. 100 µg ³H (1000 Bq/100 µl) cortisol solution was added to all serum samples after which 0.2 ml of a polyclonal rabbit antiserum was added. The sensitivity of the assay was 15 nmol/l and the coefficient of variation ranged from 5% to 8%.

The number of patients with cortisol samples available for both RIA and HPLC was 28 for FP2000, 23 for oral prednisolone, and 33 for FP500. There were no significant differences at baseline between the groups or between the methods of cortisol measurement. Both treatment with FP2000 and with oral prednisolone significantly reduced serum cortisol levels (fig 1), but suppression of serum cortisol in the oral prednisolone group using the HPLC method (~72%) was significantly larger than with the RIA method (~34%, fig 1). As expected, the difference between the cortisol levels measured by RIA and HPLC increased with higher serum prednisolone concentrations (data not shown). The difference is fully explained by the fact that serum prednisolone levels were not separately identified from cortisol by the RIA method. This crossreactivity of prednisolone with cortisol can differ considerably between laboratories and with the RIA method (monoclonal or polyclonal) used, but is always present and ranges from 10% to 100%.^{3,8-10} There were no significant differences in the change in serum cortisol levels between the HPLC and RIA methods in the inhaled fluticasone groups (FP2000 and FP500).

We conclude that determination of serum cortisol by RIA severely underestimates serum cortisol suppression over a range of 6.9–690 nmol/l serum cortisol in the presence of prednisolone. Our study shows that cortisol suppression in the presence of prednisolone should not be assessed by conventional RIA.

R J Meijer, D S Postma, H A M Kerstjens

Department of Pulmonary Diseases, University Hospital Groningen, Hanzplein 1, 9700 RB Groningen, The Netherlands; r.j.meijer@int.azg.nl

References

- 1 Levy ML, Stevenson C, Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. *Thorax* 1996;51:1087–92.

- 2 Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. *Am J Respir Crit Care Med* 1995;152:1467–73.
- 3 Meijer RJ, Kerstjens HAM, Arends LR, et al. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. *Thorax* 1999;54:894–9.
- 4 Lawrence M, Wolfe J, Webb DR, et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. *Am J Respir Crit Care Med* 1997;156:744–51.
- 5 Bosman HG, Uffelen van R, Tamminga JJ, et al. Comparison of inhaled beclomethasone dipropionate 1000 micrograms twice daily and oral prednisone 10 mg once daily in asthmatic patients. *Thorax* 1994;49:37–40.
- 6 Honour JW. Fluticasone in asthma (letter). *Thorax* 2000;55:724.
- 7 Haynes J. Validation of an ASTED/HPLC method for the determination of cortisol in human serum. ASTED BAS Analytics Ltd. Report No. R/23H37.
- 8 Huang CM, Zweig M. Evaluation of a radioimmunoassay of urinary cortisol without extraction. *Clin Chem* 1989;35:125–6.
- 9 Morineau G, Gosling J, Patricot MC, et al. Conventional chromatographic prepurification step before measurement of urinary cortisol by radioimmunoassay. *Clin Chem* 1997;43:786–93.
- 10 Chen CL, Goldberg J, Gronwall RR. Pharmacokinetics of intravenously administered prednisolone in the horse as determined by radioimmunoassay. *Chin J Physiol* 1995;38:1–6.

Smoking cessation

We welcome the study by Pelkonen *et al*¹ as a further contribution to our knowledge base on smoking cessation and its effects on pulmonary function and mortality. We feel, however, that some shortcomings in the methodology may bring into question the magnitude of the results.

Our main concern relates to the difficulties in quantifying levels of tobacco exposure. Since tobacco consumption is a continuous variable, confounding factors may occur within each group when categorised too broadly.² More information about duration and levels of smoking would help to avoid this problem. No information is given as to whether intermittent quitters returned to original habits or resumed smoking at reduced levels. Beneficial effects described in this group could therefore be due to extended periods of decreased tobacco consumption rather than a period of abstinence.

There are no data provided on smoking status from 1974 to 1989. If large numbers of those classed as intermittent quitters had permanently stopped smoking by this time, the value of temporary quitting would be overestimated. Furthermore, no data exist on the duration of periods of abstinence among intermittent quitters. If a significant proportion of this group exhibited prolonged periods of smoking cessation, the relevance of this study to short term quitters is debatable.

Even accepting the beneficial effects of intermittent quitting, we question the importance of this finding in a public health setting. Surely the main healthcare message must remain the same: permanent smoking cessation should remain the goal and is superior to intermittent quitting. However, we recognise that this finding could provide encouragement to those who have relapsed following

If you have a burning desire to respond to a paper published in *Thorax*, why not make use of our "rapid response" option? Log on to our website (www.thoraxjnl.com), find the paper that interests you, and send your response via email by clicking on the "eLetters" option in the box at the top right hand corner.

Providing it isn't libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on "read eLetters" on our homepage.

The editors will decide as before whether to also publish it in a future paper issue.

an attempt to quit smoking and reassure them that their efforts have not been in vain. This could provide the motivation needed for a second and possibly successful attempt to quit.

L Dunn, A Ogilvie

Department of Epidemiology and Public Health,
University of Newcastle Medical School, Newcastle
upon Tyne NE2 4HA, UK

References

- 1 **Pelkonen M**, Notkola IL, Tukiainen H, *et al*. Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among Finnish cohorts of the Seven Countries Study. *Thorax* 2001;**56**:703–7.
- 2 **Leon DA**. Failed or misleading adjustment for confounding. *Lancet* 1993;**342**:479–81.

Authors' reply

Lorna Dunn and Aileen Ogilvie make an important point that the confounding effect of tobacco consumption on the decline in pulmonary function may occur when the levels of tobacco exposure are categorised too broadly. They think that the benefit of intermittent quitting on the decline in FEV_{0.75} in our study might be explained by decreased tobacco consumption after periods of abstinence rather than by the periods of abstinence per se. They also point out that, if a considerable proportion of intermittent quitters stopped smoking permanently between 1974 and 1989, it would have led to overestimation of the value of temporary quitting. The third question concerns the duration of periods of abstinence.

In our study the data on smoking habits were recorded at baseline and in subsequent re-examinations by a standard questionnaire. The interval between examinations was usually 5 years. Intermittent quitters were either baseline past smokers who smoked in at least one of the subsequent re-examinations or baseline smokers who were quitters in one or more re-examinations but relapsed back to smoking later. To be recorded as a quitter in an examination a subject had to have given up smoking more than a year previously. During the first 15 years, 27 of 75 intermittent quitters were recorded as quitters in one examination (corresponding to at least 1 year of abstinence), 32 were recorded as quitters in two examinations (corresponding to at least 2 years of abstinence), and 16 were recorded as quitters in three examinations (corresponding to at least 3 years of abstinence).

During the first 15 years intermittent quitters reduced the number of cigarettes smoked daily compared with continuous smokers, although not significantly. To measure tobacco consumption more precisely, a new variable was constructed by computing the mean reported daily cigarette consumption at each examination point. For intermittent quitters only, the data from the examinations when they reported smoking were used in making up this variable. When we then additionally adjusted our analyses for this new variable, the decline in FEV_{0.75} during the first 15 years was still significantly less among intermittent quitters than in continuous smokers (data available from the authors on request). The benefit of intermittent quitting on the decline in pulmonary function therefore also seems to be mediated through periods of abstinence.

Among both intermittent quitters and continuous smokers there were study subjects who stopped smoking permanently between 1974 and 1989. The proportion of such study subjects was greater among intermittent

quitters than among continuous smokers. However, when we made additional adjustments for both the mean daily tobacco consumption during the first half of the follow up period and for quitting smoking during the latter half of the follow up period, intermittent quitters still lost less FEV_{0.75} during the whole 30 years than continuous smokers (data available from the authors on request).

In conclusion, it seems that some protection may be gained from periods of abstinence, although we agree that the main goal should be permanent smoking cessation.

M Pelkonen, I-L Notkola, H Tukiainen, M Tervahauta, J Tuomilehto, A Nissinen

Department of Pulmonary Diseases, Kuopio
University Hospital and Department of Public Health
and General Practice, University of Kuopio, P O
Box 1627, FIN-70211 Kuopio, Finland;
Margit.Pelkonen@uku.fi

Fibrosing alveolitis in patients with RA

We read with interest the paper by Dawson *et al*¹ on the prevalence of fibrosing alveolitis (FA) diagnosed by HRCT scanning in rheumatoid arthritis (RA). This well designed cross sectional study estimates the prevalence of FA at 19% in patients with RA irrespective of respiratory symptoms. This is in keeping with current literature and our earlier report of 20% in unselected patients with RA not suspected of having interstitial lung disease (ILD).²

However, neither of these studies has been sufficiently powered to assess a possible association of smoking with ILD. Smoking may adversely affect the outcome of ILD in RA and Saag *et al*³ suggested that smoking was the most consistent independent predictor of ILD patterns in lung function tests and chest radiographs in RA. One of our previous studies⁴ reported a prevalence of ILD of only 5% on HRCT scanning in a cohort of 20 never smokers with RA, while Dawson *et al* reported a prevalence of 11% in never smokers compared with 22% in smokers. There is therefore evidence of a trend towards an association between ILD and smoking which could be explored in a larger study. However, a sample size of 450 patients would be needed to test the hypothesis that smokers are twice as likely to develop ILD in RA than never smokers (95% confidence; power = 80%; smoker/never smoker ratio 2:1).

We agree with the authors that further work on the natural progression of FA diagnosed by HRCT scanning in RA is due. We have commenced a longitudinal prospective study of 18 RA patients with ILD diagnosed by HRCT scanning compared with a cohort of patients with cryptogenic fibrosing alveolitis (CFA) matched for age, sex, smoking, and respiratory symptoms.⁵ There are significant baseline differences in clinical and radiological features between these two groups. Clubbing and honeycomb appearance on the HRCT scan is more common in patients with CFA while ground glass appearance is more common in RA patients with ILD. The presence of rheumatoid factor appears to be protective against honeycombing in both groups. These differences in clinical and HRCT features may be important predictors of outcome.

V Saravanan, C A Kelly

Queen Elizabeth Hospital, Gateshead NE9 6SX,
UK

References

- 1 **Dawson JK**, Fewins HE, Desmond J, *et al*. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. *Thorax* 2001;**56**:622–7.
- 2 **McDonagh J**, Greaves M, Wright AR, *et al*. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. *Br J Rheumatol* 1994;**33**:118–22.
- 3 **Saag KG**, Kolluri S, Schwartz DA, *et al*. Rheumatoid arthritis lung disease. Determinants of radiographic and physiological abnormalities. *Arthritis Rheum* 1996;**39**:1711–9.
- 4 **Hassan WU**, Keaney NP, Holland CD, *et al*. High resolution tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. *Ann Rheum Dis* 1995;**54**:308–10.
- 5 **Rajasekaran BA**, Shovlin D, Lord P, *et al*. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis. *Rheumatology* 2001;**40**:1022–5.

Authors' reply

We are pleased to receive the letter from Saravanan and Kelly in response to our recent publication in *Thorax*.¹ The relationship between smoking and RA associated FA is an interesting one. There is no consistent finding in the literature of smoking and RA associated FA and, as far as we are aware, no prospective HRCT based study has shown a statistically significant association between RA associated FA and smoking. In the study by Cortet *et al*² 68 patients with RA were prospectively studied with HRCT scanning. Cigarette smoking was less prevalent than in the North of England and the ratio of smokers to non-smokers was 1:3. No statistical association was seen linking smoking and interstitial lung disease (ILD) and a prevalence of 20% of ILD (17% ground glass pattern and 2.9% reticular pattern) was still found. It is true that in our study the absolute risk of ever smoking cannot be excluded as a risk factor for FA as the number of lifelong non-smokers is small; however, the pack year data are adequately powered to show no statistically significant difference.

With regard to the paper by Rajasekaran *et al*,³ we feel it necessary to point out that the patients in their study with FA and RA had the diagnosis confirmed by HRCT scanning and, in addition, were symptomatic with dyspnoea, bibasal crackles, restrictive pulmonary function tests, and chest radiographic changes of FA. We are sure this will provide very valuable information about the progression of FA in patients with RA but it will not add to our knowledge on the outcome of HRCT changes detected at a subclinical stage.

Rajasekaran *et al* found honeycombing on the HRCT scan in three of 18 patients with RA associated ILD and in four of 18 patients with CFA; this difference is not statistically significant.³ None of these patients was rheumatoid factor positive, which has led the authors to postulate that rheumatoid factor may be protective against honeycombing in ILD. These findings are in direct contrast to those of Muller-Leisse *et al*⁴ who found higher levels of rheumatoid factor to be associated with ground glass changes and honeycombing on the HRCT scan, and also to McDonagh *et al*⁵ who reported that at least five of 16 patients (31%) had honeycombing and were rheumatoid factor positive. This finding is particularly interesting given that there is evidence in the literature of smoking being associated with seropositivity for rheumatoid factor in patients with⁶ and without RA.^{7,8} We

would suggest that larger studies need to be undertaken and explored for confounding factors such as smoking before a statement can be made that rheumatoid factor is protective against honeycombing.

**J K Dawson, J Desmond, M P Lynch,
D R Graham**

Department of Rheumatology, St Helen's Hospital,
St Helen's, Merseyside, UK;
twodocs@doctors.org.uk

References

- 1 Dawson JK, Fewins HE, Desmond J, *et al*. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. *Thorax* 2001;**56**:622–7.
- 2 Cortel B, Perez T, Roux N, *et al*. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. *Ann Rheum Dis* 1997;**56**:596–600.
- 3 Rajasekaran BA, Shovlin D, Lord P, *et al*. Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis. *Rheumatology* 2001;**40**:1022–5.
- 4 Muller-Leisse C, Bussmann A, Meyer O, *et al*. Pulmonary manifestations in rheumatoid arthritis: high-resolution computed tomography in correlation with the skeletal changes and the laboratory chemical changes. *Rofo Fortschr Geb Röntgenstr Neuen Bildgeb* 1996;**165**:438–44.
- 5 McDonagh J, Greaves M, Wright AR, *et al*. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. *Br J Rheumatol* 1994;**33**:118–22.
- 6 Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. *J Rheumatol* 2000;**27**:630–7.
- 7 Tuomi T, Heliövaara M, Palosuo T, *et al*. Smoking, lung function, and rheumatoid factors. *Ann Rheum Dis* 1990;**49**:753–6.
- 8 Jonsson T, Thorsteinsson J, Valdimarsson H. Does smoking stimulate rheumatoid factor production in non-rheumatic individuals? *APMIS* 1998;**106**:970–4.

Measuring granulocyte apoptosis in airway inflammation

We read with interest the paper by Turlej *et al* describing enhanced survival of lung granulocytes in an animal model of asthma.¹ As discussed by the authors, modulation of immune cell apoptosis is likely to be important in controlling inflammatory processes, and the paper enhances our understanding of this.

However, we feel that there are some methodological problems with the study. Firstly, the animal model they describe, though having some similarities with asthma, is closer to chronic obstructive pulmonary disease (COPD). Neutrophils are the predominant inflammatory cells in this model. This condition is often known as COPD in horses.²

Secondly, although the authors refer to the use of annexin V (AV) and propidium iodide (PI), they do not describe the methodology used or how they interpreted the staining with AV and PI. This is important because there are controversies surrounding the interpretation of this method of assessing apoptosis.³ The interpretation of the various staining patterns is controversial. In addition, at least two methods should be used to confirm apoptosis,^{4,5} and only one is used in the study.

It is noted that the blood granulocytes are isolated by use of a density gradient. Density gradients may interfere with some neutrophil functions⁶ and this must be borne in mind when interpreting these results. Additionally, BAL granulocytes from healthy horses were isolated by use of a density gradient, whereas this was not used for the diseased horses. This difference of methods introduces a potential bias into the study. We have previously attempted to isolate neutrophils from human BAL fluid with no success (unpublished observations) and would be interested to know if the authors achieved this separation easily. We are also surprised at the viability of >90%. Cell viability is likely to diminish with increasing rates of apoptosis, and it is notable that the BAL granulocytes from healthy horses have apoptotic rates of around 40%.

This study is interesting, but the methodological issues raised must be considered in interpreting the results.

M G Kelly, J S Elborn

Respiratory Research Group, Department of Respiratory Medicine, Belfast City Hospital, Belfast, UK

M G Kelly, V Brown, M Ennis

Department of Clinical Biochemistry, Centre for Inflammation, Infection and Repair, Queens University, Belfast, UK

Correspondence to: Dr M Kelly, Department of Respiratory Medicine, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK; m.g.kelly@qub.ac.uk

References

- 1 Turlej RK, Fievez L, Sandersen CF, *et al*. Enhanced survival of lung granulocytes in an animal model of asthma: evidence for a role of GM-CSF activated STAT5 signalling pathway. *Thorax* 2001;**56**:696–702.
- 2 Raulo SM, Sorsa T, Tervahartila T, *et al*. MMP-9 as a marker of inflammation in tracheal epithelial lining fluid (TELF) and in bronchoalveolar fluid (BALF) of COPD horses. *Equine Vet J* 2001;**33**:113–5.
- 3 <http://www.cyto.purdue.edu/hmarchiv/2000/0536.htm> (accessed 6 October 2001).
- 4 Anon. Apoptosis. Applied reagents and techniques. *Instruction manual*, 2nd ed. San Diego: Pharmingen, 1998.
- 5 <http://www.cyto.purdue.edu/hmarchiv/2000/0382.htm> (accessed 6 October 2001).
- 6 Glasser L, Fiedlerlein MT. The effect of various cell separation procedures on assays of neutrophil function. *Am J Clin Pathol* 1990;**93**:662–9.

Authors' reply

We thank Dr Kelly and colleagues for their interest in our paper. In the past equine heaves was called COPD but, because equine heaves is completely different from human COPD, specialists in the field have recommended avoiding the erroneous term "COPD" for designating this disease.¹ Indeed, it is now clear that equine heaves is very close to atopic asthma and these diseases share important characteristic features including hypersensitivity to aeroallergens, Th2 type immune response, chronic airway inflammation, reversible airway obstruction, non-specific airway hyperresponsiveness, and production of allergen specific IgE.^{2,3} It is correct that neutrophils are the predominant inflammatory cells in equine heaves, but this does not exclude the use of this model in asthma studies. Indeed, neutrophils are known to play an important role in asthma whereas recent studies have questioned the importance of eosinophils in this disease.^{4,5}

In our study only small amounts of granulocytes were recovered from the lung of the

horses so we were only able to use one method to assay these cells for apoptosis. We chose the method that has been found to be the most sensitive marker of granulocyte apoptosis—the annexin V (AV)/propidium iodide (PI) method.⁶ The results obtained with this method were interpreted as recommended: AV–/PI– cells were considered alive, AV+/PI– cells were considered apoptotic, and AV+/PI+ cells were considered necrotic. This is the first time we have heard of controversy surrounding the interpretation of the results obtained with this method, probably because they have not been published in scientific journals. According to the archives we have read using the web addresses provided by Dr Kelly and colleagues, it appears that this controversy exclusively concerns the status of AV–/PI+ cells. Such cells are uncommon and were not observed in our study.

We agree that density centrifugation may interfere with neutrophil function. To the best of our knowledge there is no other way of separating granulocytes from other cell types. As mentioned in the Methods section of our paper, cell viability of freshly isolated granulocytes was evaluated by trypan blue (TB) exclusion. The cells were then cultured for different times and assayed for apoptosis using AV/PI. Cells in an early state of apoptosis are AV+ and TB–. It is therefore not surprising to find 40% apoptotic (AV+) cells in a population where nearly all the cells (>90%) are TB–.

F Bureau

Department of Physiology, Faculty of Veterinary Medicine, University of Liège, B-4000 Liège, Belgium

References

- 1 Robinson NE. International Workshop on Equine Chronic Airway Disease. Michigan State University 16–18 June 2000. *Equine Vet J* 2001;**33**:5–19.
- 2 Eder C, Cramer R, Mayer C, *et al*. Allergen-specific IgE levels against crude mould and storage mite extracts and recombinant mould allergens in sera from horses affected with chronic bronchitis. *Vet Immunol Immunopathol* 2000;**73**:241–53.
- 3 Lavoie JP, Maghni K, Desnoyers M, *et al*. Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile. *Am J Respir Crit Care Med* 2001;**164**:1410–3.
- 4 Bryan SA, O'Connor BJ, Matti S, *et al*. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet* 2000;**356**:2149–53.
- 5 Leckie MJ, ten Brinke A, Khan J, *et al*. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet* 2000;**356**:2144–8.
- 6 Walsh GM, Dewson G, Wardlaw AJ, *et al*. A comparative study of different methods for the assessment of apoptosis and necrosis in human eosinophils. *J Immunol Methods* 1998;**217**:153–63.

CORRECTION

In the Programme and Abstracts of the British Thoracic Society Winter Meeting 2001 published in *Thorax* 2001;**56** (Supplement III), an error occurred in abstract S130 "Management of pneumothorax in a district general hospital: compliance with the BTS guidelines" by Al-Aloul M, *et al* which appeared on page iii40. The name of the second author which appeared as K U Torrey should have been K U Toori.